CN115485395A - 用于治疗癌症的包含剪接-衍生的抗原的组合物和方法 - Google Patents

用于治疗癌症的包含剪接-衍生的抗原的组合物和方法 Download PDF

Info

Publication number
CN115485395A
CN115485395A CN202180028467.5A CN202180028467A CN115485395A CN 115485395 A CN115485395 A CN 115485395A CN 202180028467 A CN202180028467 A CN 202180028467A CN 115485395 A CN115485395 A CN 115485395A
Authority
CN
China
Prior art keywords
peptide
cells
cell
cancer
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180028467.5A
Other languages
English (en)
Chinese (zh)
Inventor
邢毅
欧文·威特
约翰·菲利普斯
潘扬
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of CN115485395A publication Critical patent/CN115485395A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/812—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/86—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/884—Vaccine for a specifically defined cancer prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/92—Fusion polypeptide containing a motif for post-translational modification containing an intein ("protein splicing")domain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202180028467.5A 2020-02-14 2021-02-12 用于治疗癌症的包含剪接-衍生的抗原的组合物和方法 Pending CN115485395A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062976654P 2020-02-14 2020-02-14
US62/976,654 2020-02-14
PCT/US2021/017958 WO2021163562A2 (en) 2020-02-14 2021-02-12 Compositions and methods comprising splicing-derived antigens for treating cancer

Publications (1)

Publication Number Publication Date
CN115485395A true CN115485395A (zh) 2022-12-16

Family

ID=77295208

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180028467.5A Pending CN115485395A (zh) 2020-02-14 2021-02-12 用于治疗癌症的包含剪接-衍生的抗原的组合物和方法

Country Status (5)

Country Link
US (1) US20240182518A1 (https=)
EP (1) EP4103738A4 (https=)
JP (1) JP2023513605A (https=)
CN (1) CN115485395A (https=)
WO (1) WO2021163562A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4055182A4 (en) * 2019-11-08 2024-07-03 The Regents Of The University Of California IDENTIFICATION OF SPLICE-DRIVEN ANTIGENS FOR CANCER TREATMENT
US20250352576A1 (en) * 2022-04-01 2025-11-20 The Regents Of The University Of California Methods and compositions for treating gliomas
CN116178567B (zh) * 2022-10-28 2025-01-28 四川大学华西医院 一种靶向TGFβRII的嵌合抗原受体及其用途
EP4695284A1 (en) * 2023-04-11 2026-02-18 The Regents of University of California Human t cell receptors targeting tumor-enhanced splicing epitopes on hla-a*02:01 for small cell carcinoma

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030069181A1 (en) * 2001-05-25 2003-04-10 Wong Albert J. Alternative splice forms of proteins as basis for multiple therapeutic modalities

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
EP4012714A1 (en) * 2010-03-23 2022-06-15 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
GB201602918D0 (en) * 2016-02-19 2016-04-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
US20180305776A1 (en) * 2017-04-20 2018-10-25 The Board Of Trustees Of The Leland Stanford Junior University Myc-reporters, cells containing myc-reporters and methods of use thereof
EP4055182A4 (en) * 2019-11-08 2024-07-03 The Regents Of The University Of California IDENTIFICATION OF SPLICE-DRIVEN ANTIGENS FOR CANCER TREATMENT

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030069181A1 (en) * 2001-05-25 2003-04-10 Wong Albert J. Alternative splice forms of proteins as basis for multiple therapeutic modalities

Also Published As

Publication number Publication date
WO2021163562A2 (en) 2021-08-19
EP4103738A4 (en) 2024-05-29
EP4103738A2 (en) 2022-12-21
JP2023513605A (ja) 2023-03-31
US20240182518A1 (en) 2024-06-06
WO2021163562A3 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
ES2758173T3 (es) Receptor quimérico de antígeno (CAR) con dominios de unión a antígeno para la región constante de receptores de linfocitos T beta
JP7082055B2 (ja) 抗癌治療における組み合わせ使用のためのメソテリンキメラ抗原受容体（ｃａｒ）およびｐｄ－ｌ１阻害剤に対する抗体
US20200407460A1 (en) Human mesothelin chimeric antigen receptors and uses thereof
US10479997B2 (en) Compositions and methods for diagnosis and treatment of prostate cancer
TWI750110B (zh) 使用人類化抗-ｂｃｍａ嵌合抗原受體治療癌症
US20220380937A1 (en) Identification of splicing-derived antigens for treating cancer
CN115485395A (zh) 用于治疗癌症的包含剪接-衍生的抗原的组合物和方法
JP2021526814A5 (https=)
CN114127091A (zh) 肿瘤新抗原多肽及其用途
JP2022512872A (ja) 細胞の選択および刺激のための方法ならびにそのための装置
US12570712B2 (en) Cyclin A1 specific T cell receptors and uses thereof
BR112021008289A2 (pt) Métodos para tratamento utilizando receptores de antígeno quimérico específico para antígeno de maturação de célula b
BR112021003031A2 (pt) imunoterapia direcionada a antígenos kras ou her2
EP4291902A2 (en) Biomarkers for cancer treatment
KR20220008253A (ko) 암을 앓는 대상에서 cd8+ t 세포 의존성 면역 반응을 향상시키기 위한 방법 및 약학적 조성물
JP2020533289A (ja) 養子細胞治療を改善するための方法
CN115843317A (zh) 新型t细胞特异性及其用途
AU2023269157A1 (en) Binding proteins specific for ras neoantigens and uses thereof
WO2026059935A1 (en) Immunotherapy targeting modified kras g12v antigen
US20250049848A1 (en) Methods and compositions for altering a tumor microbiome
HK40092056A (zh) 用於治疗癌症的剪接衍生抗原的鉴定
WO2025050009A2 (en) Identification of targets for immunotherapy in melanoma using splicing-derived neoantigens
HK40113193A (zh) 靶向ndc80抗原的肽和经改造t细胞受体及使用方法
BR112020025048A2 (pt) Receptores de antígeno quimérico de bcma e usos dos mesmos
Duhen et al. Providence St. Joseph Health Digital Commons

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination